Working to facilitate rapid translation of scientific discoveries into therapeutics

Pele Chong

Dr. Chong11

Pele Chong, PhD

Dr. Chong obtained his BSc (Sept/1978) and PhD (Feb/1983) from the department of Biochemistry in the University of Alberta, Edmonton, Canada. He was trained as a protein chemist and specialized in peptide synthesis for protein structure and function studies. Dr. Chong then worked on the recombinant rubella subunit vaccine development for 2 years as a MRC postdoctoral fellow at the department of Pathology in the University of British Columbia. Dr. Chong then moved to Toronto and had spent 15 years at Connaught Laboratory Limited (now called Sanofi Pasteur) in human vaccine research and development. During his tenure there as a Research Scientist (July/1985) and Director (July/1994), Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b (Hib) and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to Phase I clinical trials in 1994. In June/2000 Dr. Chong moved to New York and joined a Biotechnology company United Biomedical Inc. (UBI) where he helped developing a peptide-based animal Foot-Mouth Disease vaccine for pig that is currently licensed in China. In June/2003, Dr. Chong was recruited and joined NHRI to develop and establish the Vaccine Research and Development Center (VRDC). To facilitate and implement the Taiwanese Government Vaccine R&D, Self-Manufacturing and Supply strategic plans, VRDC starts from 1 person (Dr. Chong) in June/2003 and now has >140 staff operating the fully integrated Biotech-like organization structure. Dr. Chong has authored over 140 original research articles and has over 80 patents filed and/or granted.

2013-2021©European Society for Translational Medicine (EUSTM)